Rasagiline (Azilect)

A monoamine oxidase type B inhibitor approved for treating Parkinson’s disease.

Attenuation of Disease Progression with Azilect Given Once Daily (ADAGIO) trial of 1176 untreated Parkinson’s disease patients randomly assigned to receive rasagiline 1 or 2 mg/day or placebo in an early treatment or late treatment groups: early treatment with 1 mg provided benefits consistent with possible disease modifying effect, but early treatment with 2 mg per day did not.

Leave a Reply

Your email address will not be published. Required fields are marked *